Revolutionary fully implanted hearing device tested in adults

NCT ID NCT06699797

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a fully implanted cochlear implant called Acclaim CI in 56 adults with severe to profound hearing loss. The goal is to see if it helps them hear words better than before and to check for any medical problems. Participants get the implant and are followed for up to 2 years.

Why investors are watching

Envoy Medical is a very small publicly traded company, and this trial is its main event. The study tests whether its fully implanted Acclaim cochlear implant helps adults with severe to profound hearing loss recognize words better than before surgery, and whether the device is safe. For a micro-cap company, the outcome of this 56-patient trial could determine the value of its entire pipeline.

If it works: If the trial shows clear word-recognition gains and an acceptable safety profile, Envoy could have a marketable product in a field where fully implanted devices are rare. That result might attract partners or funding to bring the device through regulatory approval.

If it fails: Clinical trials often fail to show meaningful benefit or reveal unexpected safety problems. A negative or delayed result could leave Envoy without a clear path to revenue, which would be a serious setback for a company of its size.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 56 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed and dated informed consent form. 2. Able to understand and comply with the requirements of the Study, including surgery and post-implant rehabilitation. 3. Ability to read, write, comprehend, and speak fluently in English. 4. Post-lingually deafened. 5. 18 years of age or older at the time of informed consent. 6. Good health and absence of significant comorbidities, in the opinion of the Principal Investigator. 7. At least 30 days of experience with appropriate bilaterally fit hearing aids. 8. Ear to be implanted has severe to profound hearing loss defined as pure tone average at 500, 1000, 2000 and 4000 Hz ≥ 70 dB. 9. Contralateral ear has moderately severe to profound hearing loss defined as pure tone average at 500, 1000, 2000 and 4000 Hz ≥ 60 dB. 10. Limited benefit from amplification defined as CNC monosyllabic word recognition ≤ 40% in the ear to be implanted and ≤ 60% in the contralateral ear, in the aided condition. 11. Normal middle ear function based on otoscopy and tympanometry. 12. An accessible cochlear lumen and intact cochlear nerve, and no known lesions on the auditory nerve or auditory central nervous system, on the ear to be implanted confirmed with MRI or CT scan. Exclusion Criteria: 1. Documented duration of severe to profound hearing loss for 20 or more years. 2. Previous cochlear implantation in either ear. 3. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array. 4. Active external or middle ear pathology (i.e., infections, tympanic membrane perforation, or ossicular chain issues) in the ear to be implanted at the time of screening or in the past 6 months, that could impact the proper functioning of the device. 5. Known history of chronic eustachian tube dysfunction. 6. Prior surgery in the middle ear, inner ear, neck, or infraclavicular region which is anticipated to prevent proper placement or function of the Acclaim CI. 7. Hearing loss/disorder of retrocochlear origin. 8. Diagnosis of auditory neuropathy. 9. Currently using other active implants that are expected to interfere with the Acclaim CI position or function. 10. Known hypersensitivity to silicone rubber, polyurethane, stainless steel, titanium, platinum, or gold. 11. Known hypersensitivity or contraindications to procedural or post-procedural medications that cannot be adequately managed medically. 12. Pregnancy at the time of Acclaim CI implantation. 13. Known need for MRI or ionizing radiation treatment during Study participation. 14. Unrealistic expectations on the Participant's part regarding the possible benefits, risks, and limitations inherent to the surgical procedure and use of the Acclaim CI, in the Principal Investigator's opinion. 15. Unwillingness or inability to comply with all investigational requirements. 16. Additional conditions that would prevent completion of all Study requirements, in the opinion of the Principal Investigator. 17. Participation in an investigational drug study or another device study within 3 months of the Screening Visit. 18. Previous history of meningitis. 19. Deafness, in the ear to be implanted, due to: 1. a damaged or absent tympanic membrane, 2. a damaged or absent middle ear, 3. an absent cochlea, 4. lesions on the acoustic nerve, or 5. lesions on the central auditory pathway

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sensori-neural deafness are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Center for Neurosciences Ear and Hearing Center

    Tucson, Arizona, 85718, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Hearts for Hearing

    Oklahoma City, Oklahoma, 73114, United States

  • MUSC Health

    Charleston, South Carolina, 29425, United States

  • Mayo Clinic

    Rochester, Minnesota, 55902, United States

  • Shohet Ear Associates

    Seal Beach, California, 90740, United States

  • University of Florida Health

    Gainesville, Florida, 32607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.